| Acceptance No. | Drug Name | Active Ingredient | Dosage Form | Classification | Submission | Acceptance Date | Manufacturers | Manufacturers | Review Status | Status Date | View |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CXSL2000035 | 注射用重组肿瘤酶特异性干扰素α-2b Fc融合蛋白 | Lyophilized | Biological Products(1) | New Drug Application | 2020-02-25 | 珠海市丽珠单抗生物技术有限公司 | Livzon Mabpharm INC | In Review | 2020-02-24 | view |